Margetuximab

Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer[1].

Product Specifications

CAS Number

[1350624-75-7]

Product Name Alternative

MGAH-22

UNSPSC

12352203

Target

EGFR

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/margetuximab.html

Purity

99.0

Solubility

H2O

Smiles

[Margetuximab]

Molecular Weight

(146.1 kDa)

References & Citations

[1]Nordstrom JL, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13 (6) :R123. doi:10.1186/bcr3069